Stockreport

Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

Advaxis, Inc.  (ADXS) 
Last advaxis, inc. earnings: 9/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.advaxis.com
PDF ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previo [Read more]